Dexanabinol fails brain injury Phase III

Pharmos PARS was down $2.34 (66%) to $1.17 on 40.8 million shares

Read the full 123 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE